Carroll Financial Associates’s PDL BioPharma, Inc. PDLI Stock Holding History

Carroll Financial Associates’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-19	Closed	–	–	1830
2019 Q2	$0	Buy	+19	New	+$62	﹤0.01%	1802
2015 Q4	–	Sell	-737	Closed	-$3K	–	1230
2015 Q3	$3K	Buy	737 +20	+3%	+$115	﹤0.01%	953
2015 Q2	$5K	Buy	717 +17	+2%	+$114	﹤0.01%	875
2015 Q1	$5K	Hold	700	–	–	﹤0.01%	647
2014 Q4	$5K	Hold	700	–	–	﹤0.01%	589
2014 Q3	$5K	Hold	700	–	–	﹤0.01%	677
2014 Q2	$7K	Hold	700	–	–	﹤0.01%	667
2014 Q1	$6K	Hold	700	–	–	﹤0.01%	639
2013 Q4	$5K	Buy	+700	New	+$5.9K	﹤0.01%	623

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Carroll Financial Associates's PDLI Position: Q3 2019 in Review

Carroll Financial Associates sold out of PDL BioPharma, Inc. (PDLI) in Q3 2019, closing a stake of 19 shares.

Carroll Financial Associates first reported a position in PDLI in Q4 2013 and held it in 9 quarters. The position peaked at $7K in Q2 2014. 140 funds tracked by Wall St. Rank hold PDLI as of Q3 2019.

Carroll Financial Associates reported no remaining PDL BioPharma, Inc. position as of Q3 2019 after selling out during the quarter.
Carroll Financial Associates sold 19 PDL BioPharma, Inc. shares in Q3 2019.
Carroll Financial Associates first reported a position in PDL BioPharma, Inc. in Q4 2013 and held it in 9 quarters.
Carroll Financial Associates's PDL BioPharma, Inc. position peaked at $7K in Q2 2014.
140 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2019.

Based on Carroll Financial Associates's 13F filing for Q3 2019, filed 9 Oct 2019.